Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

Generic tenofovir disoproxil fumarate/emtricitabine the most frequently prescribed medication since 2021. (HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, ...

It was first approved for use as a pre-exposure prophylaxis (PrEP) — medication to prevent HIV infections — in the United States in 2012. It has since been used globally as a standard method ...

If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them ... one in 25 people live with HIV. Lenacapavir is a ...

One of the most important medical breakthroughs in the fight against HIV has been the use of antiretroviral treatments for prevention. Called pre-exposure prophylaxis ... of a new drug, called ...

ONLY 132 people in 2023 were reported to be on pre-exposure prophylaxis (PrEP), a critical HIV prevention drug freely available ... and those who do not consistently use condoms would benefit ...

Additionally, Lenacapavir is currently under investigation for the prevention of HIV (pre-exposure prophylaxis ... was approved for use in HIV-positive adults with multi-drug resistance by the ...